Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial

Authors
Joly, V Moroni, M Concia, E Lazzarin, A Hirschel, B Jost, J Chiodo, F Bentwich, Z Love, WC Hawkins, DA Wilkins, EGL Gatell, AJ Vetter, N Greenwald, C Freimuth, WW De Cian, W
Citation
V. Joly et al., Delavirdine in combination with zidovudine in treatment of human immunodeficiency virus type 1-infected patients: Evaluation of efficacy and emergence of viral resistance in a randomized, comparative phase III trial, ANTIM AG CH, 44(11), 2000, pp. 3155-3157
Citations number
8
Categorie Soggetti
Microbiology
Journal title
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
ISSN journal
00664804 → ACNP
Volume
44
Issue
11
Year of publication
2000
Pages
3155 - 3157
Database
ISI
SICI code
0066-4804(200011)44:11<3155:DICWZI>2.0.ZU;2-S
Abstract
We compared the activity of delavirdine (DLV) plus zidovudine (AZT) (n = 30 0) with that of AZT (n = 297) against human immunodeficiency virus type 1 i n a randomized, double-blind, placebo-controlled trial. DLV exerted a trans ient antiviral effect, and mutations for resistance to DLV were found in mo re than 90% of subjects at week 12. The K103N mutation, which confers nonnu cleoside reverse transcriptase inhibitor cross-resistance, was found in 85% of the patients.